Gilead Sciences (GILD) Dividends Paid - Common Growth (3y) (2018 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Div. Paid (Common) Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
15.02% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
2.10% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
5.06% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
4.34% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
6.10% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
2.39% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
2.01% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
2.37% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
2.39% |
| Dec 31, 2025 |
2.21% |
| Sep 30, 2025 |
2.17% |
| Jun 30, 2025 |
2.27% |
| Mar 31, 2025 |
2.51% |
| Dec 31, 2024 |
2.86% |
| Sep 30, 2024 |
2.58% |
| Jun 30, 2024 |
2.70% |
| Mar 31, 2024 |
2.24% |
| Dec 31, 2023 |
2.68% |
| Sep 30, 2023 |
3.24% |
| Jun 30, 2023 |
3.28% |
| Mar 31, 2023 |
3.50% |
| Dec 31, 2022 |
4.84% |
| Sep 30, 2022 |
4.95% |
| Jun 30, 2022 |
4.79% |
| Mar 31, 2022 |
4.62% |
| Dec 31, 2021 |
6.70% |
| Sep 30, 2021 |
6.65% |
| Jun 30, 2021 |
6.53% |
| Mar 31, 2021 |
6.84% |
| Dec 31, 2020 |
8.58% |
| Sep 30, 2020 |
8.29% |
| Jun 30, 2020 |
8.39% |
| Mar 31, 2020 |
8.36% |
| Dec 31, 2019 |
9.29% |
| Sep 30, 2019 |
9.01% |
| Jun 30, 2019 |
8.97% |
| Mar 31, 2019 |
11.51% |
| Dec 31, 2018 |
6.23% |
| Sep 30, 2018 |
5.74% |
| Jun 30, 2018 |
5.34% |
